Liangmei He

Johns Hopkins University — United States

Immunology and Microbiology · Life Sciences

37h-index4.1kcitations96works1.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(60), Cancer Immunotherapy and Biomarkers(23), Immune Cell Function and Interaction(23), RNA Interference and Gene Delivery(18), CAR-T cell therapy research(14)

Publications96 total

Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity

1 cited

Gene Therapy·2024· 1 cited

SSupplementary Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Data from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure Legend from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplementary Figure Legends from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Data from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

SSupplementary Figure 1 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplementary Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplemental Figure Legend from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplementary Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplementary Figure Legends from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ

2023Open Access

Supplementary Figure 2 from Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion

2023Open Access

Supplementary Figure 2 from Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70

2023Open Access

Supplementary Figure 3 from Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion

2023Open Access

Supplementary Figure 2 from Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion

2023Open Access

Data from Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70

2023Open Access

page 1 of 5Next →

Frequent Co-authors

Chien‐Fu Hung(43), T.‐C. Wu(33), Ya-Chea Tsai(14), Morris Ling(12), Wen‐Fang Cheng(10), Tae Woo Kim(10), Shiwen Peng(9), Keng‐Fu Hsu(8), Jeremy Juang(8), David A. Boyd(8), Zhiping Liu(7), Chee‐Yin Chai(6), Cornelia L. Trimble(5), Richard B.S. Roden(5), T-C Wu(5), Cheng‐Tao Lin(4), Sara I. Pai(4), Raphael P. Viscidi(4), J. Marie Hardwick(4), Ruey-Shyang Soong(4)